Cited by 21Nanoparticle-Based Drug DeliveryAdvancements in Transdermal Drug DeliveryAdvanced Drug Delivery Systems

The DOI matches its Crossref record; the references it cites are not checked yet.

Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases

Abstract

Autoimmune diseases are collectively addressed as chronic conditions initiated by the loss of one's immunological tolerance, where the body treats its own cells as foreigners or self-antigens. These hay-wired antibodies or immunologically capable cells lead to a variety of disorders like rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis and recently included neurodegenerative diseases like Alzheimer's, Parkinsonism and testicular cancer triggered T-cells induced autoimmune response in testes and brain. Conventional treatments for autoimmune diseases possess several downsides due to unfavourable pharmacokinetic behaviour of drug, reflected by low bioavailability, rapid clearance, offsite toxicity, restricted targeting ability and poor therapeutic outcomes. Novel nanovesicular drug delivery systems including liposomes, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes and biologically originated exosomes have proved to possess alluring prospects in supporting the combat against autoimmune diseases. These nanovesicles have revitalized available treatment modalities as they are biocompatible, biodegradable, less immunogenic and capable of carrying high drug payloads to deliver both hydrophilic as well as lipophilic drugs to specific sites via passive or active targeting. Due to their unique surface chemistry, they can be decorated with physiological or synthetic ligands to target specific receptors overexpressed in different autoimmune diseases and can even cross the blood-brain barrier. This review presents exhaustive yet concise information on the potential of various nanovesicular systems as drug carriers in improving the overall therapeutic efficiency of the dosage regimen for various autoimmune diseases. The role of endogenous exosomes as biomarkers in the diagnosis and prognosis of autoimmune diseases along with monitoring progress of treatment will also be highlighted.

Overview

Integrity signals

Registry

Crossref · 10.2174/1381612826666200523174108

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists haven’t been fetched yet

References 153 · Cited by 21

Research works printed but not linked: 5

  1. DeMaagd G.; Philip A.; Parkinson’s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P 2015,40(8),504-532
  2. Funk M; Schulze B; Guenzi E; Cationic liposomal preparations for the treatment of rheumatoid arthritis 2009
  3. Stepanov A.V.; Belogurov A.A.; Mamedov A.E.; Therapeutic effect of encapsulated into the nanocontainers MBP immunodominant peptides on EAE development in DA rats. Bioorg Khim 2012,38(3),306-314
  4. Madhavi N.; Sudhakar B.; Ratna J.V.; Colloidal dispersions (liposomes and ethosomes) for skin drug delivery and their role on rheumatoid arthritis 2016,1
  5. Thadanki M.; Babu A.K.; Review on ethosomes: A novel approach of liposomes 2015,6

Metadata

Authors
Neupane, Y. R., Mahtab, A., Siddiqui, L., Singh, A., Gautam, N., Rabbani, S. A., Goel, H., & Talegaonkar, S.
Affiliations
  • National University of Singapore (SG)
  • Jamia Hamdard (IN)
  • Delhi Pharmaceutical Science and Research University (IN)
  • Ras al-Khaimah Medical and Health Sciences University (AE)
  • Baba Farid University of Health Sciences (IN)
Corresponding author
Talegaonkar, Sushama
Venue
Current Pharmaceutical Design
Published
2020-12-12
Volume
26
Issue
42
Pages
5488-5502
ISSN
1381-6128 (ISSN-L)
OpenAlex
W3026937918
Cited by
21
References
153
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 2
FWCI
0.22
Type
journal article
Language
en
Open access
closed
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
autoimmune disease, liposomes, niosomes, proniosomes, ethosomes, transfersomes, pharmacosomes, exosomes, active targeting, passive targeting, blood-brain barrier, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, exosomal biomarkers, drug carriers
MeSH terms
Autoimmune Diseases, Drug Carriers, Humans, Liposomes, Male, Testicular Neoplasms, Drug Delivery Systems, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases. https://app.cochat.ai/papers/10.2174/1381612826666200523174108
The paper
Neupane, Y. R., Mahtab, A., Siddiqui, L., Singh, A., Gautam, N., Rabbani, S. A., Goel, H., & Talegaonkar, S. (2020). Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases. Current Pharmaceutical Design. https://doi.org/10.2174/1381612826666200523174108